A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, ...

Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...